The Conversation (0)
The Financial Post published a profile of Miraculins Inc. (TSXV:MOM), a medical device company focused on developing and marketing its Scout DS® diabetes screening technology.
As quoted in the market news:
The economic argument for early diabetes screening is compelling. As prediabetes progresses to diabetes, the incremental costs rise to an average of $37,000 per patient per year. This progression can be slowed or even thwarted by lifestyle and dietary changes. Unchecked, complications from diabetes can include blindness, heart disease, stroke, kidney disease, nerve damage, erectile dysfunction, amputation, and death.
Moreau commented:
Diabetes is the world’s fastest growing disease. The Scout DS® technology is positioned to make a significant impact on screening for pre-diabetes and type 2 diabetes. Our device is mobile and doesn’t require needles, blood draw, fasting or waiting. You just put your arm on it, the test operator initiates the scan and measurement, and you receive your results in under 90 seconds.
Part of the function of the Scout DS® risk assessment is to get to the right people – those most vulnerable to diabetes based on age or a combination of age and risk factors – and motivate them to see their healthcare provider to get a full diagnostic test.
Click here to read the full Financial Post article.
Click here to view the Miraculins Inc. (TSXV:MOM) profile.